Croissy-Beaubourg (France), April 4, 2019 5:45pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, announced that it has entered into a settlement agreement with HOB Biotech to end…
THERADIAG will have access to IMMUNODIAGNOSTIC SYSTEMS’ latest generation IDS-i10® automated CLIA analysis technology, dedicated to biotherapy monitoring IMMUNODIAGNOSTIC SYSTEMS will market THERADIAG’s TRACKER® range in 33 countries Croissy-Beaubourg (France), April 1, 2019 6:00pm CEST –…
Growth of 17% in sales of Tracker kits for routine useNet loss before non-recurring items of €0.4 million, close to breakevenCash position: €3.4 million Croissy-Beaubourg, March 27, 2019 – 5:45pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company…